Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?
Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?
What's Inside the Q&A:
Launch Path Decision
– Explore how biopharma leaders weigh the pros and cons of launching independently versus partnering in Europe.
Investment vs. Return
– Understand what shapes the financial calculus behind building a European presence or sharing the load.
Market Fit Factors
– See which product and pipeline traits make a self-launch realistic-or why a partner might add more value.
Strategic Evolution
– Discover how hybrid and staged models let companies balance control, speed, and long-term ambition.
